Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

Two people are wheeled into a hospital at the same time: one for a heart attack and one for an opioid overdose. You might ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

A heart attack and broken heart syndrome share similar symptoms But the two are separate conditions requiring distinct ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...